Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- N/A
Select metals/mining stocks trading lower:
- SSRI -3.6%, GFI -3.6%, GOLD -1.9%, NEM -1.9%, RGLD -1%
Other news:
- NEOT -69.8% (announces top-line results for Phase 2 proof-of-concept study of LIPO-202)
- MTNB -48.7% (topline data from its Phase 2 safety, tolerability and efficacy study of MAT2203 did not meet primary endpoint)
- DRYS -9.8% (provides Kalani Investments update)
- AMAG -7.4% (FDA Filing Acceptance of Supplemental NDA for Makena subcutaneous auto-injector; reaffirms 2017 financial guidance)
- AGIO -6.9% (reports new data from DRIVE PK study; Program on track to enter global pivotal development in 1H18)
- SGEN -6.7% (Seattle Genetics and Takeda Pharmaceutical (TKPYY) announce that the Phase 3 ECHELON-1 clinical trial met its primary endpoint)
- DMRC -3.4% (to sell 500,000 common shares in a registered direct offering to a certain investor at a price of $35.55 per share)
- BBRY -1.3% (continued weakness)
Analyst comments:
- SSYS -2.8% (downgraded to Sell from Neutral at Goldman)
- INTU -0.9% (downgraded to Neutral from Buy at Citigroup)